CEACAM1 in malignant melanoma: A diagnostic and therapeutic target

Current Topics in Medicinal Chemistry

Volumn 12, Issue 1, 2012, Pages 3-10

  Sapoznik, S ^a   Ortenberg, R ^a,b   Schachter, J ^a   Markel, G ^a,b,c  

^a Cancer Research Center   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Biomarker; Cancer; CEACAM1; Immunotherapy; Lymphocytes; Melanoma

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; INTERLEUKIN 2;

CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DRUG MEGADOSE; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD; CELL ADHESION MOLECULES; HUMANS; IMMUNOTHERAPY; MELANOMA; MOLECULAR TARGETED THERAPY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855837412     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612798919259     Document Type: Review

References (107)

1. Gray-Owen, S.D.; Blumberg, R.S. CEACAM1: contact-dependent control of immunity. Nat. Rev. Immunol., 2006, 6(6), 433-446.
2. Kuespert, K.; Pils, S.; Hauck, C.R. CEACAMs: their role in physiology and pathophysiology. Curr. Opin. Cell. Biol., 2006, 18(5), 565-571.
3. Huang, J.; Simpson, J.F.; Glackin, C.; Riethorf, L.; Wagener, C.; Shively, J.E. Expression of biliary glycoprotein (CD66a) in normal and malignant breast epithelial cells. Anticancer Res., 1998, 18(5A), 3203-3212.
4. Huang, J.; Hardy, J.D.; Sun, Y.; Shively, J.E. Essential role of biliary glycoprotein (CD66a) in morphogenesis of the human mammary epithelial cell line MCF10F. J. Cell. Sci., 1999, 112 (Pt 23), 4193-4205.
5. Muller, M.M.; Singer, B.B.; Klaile, E.; Obrink, B.; Lucka, L. Transmembrane CEACAM1 affects integrin-dependent signaling and regulates extracellular matrix protein-specific morphology and migration of endothelial cells. Blood, 2005, 105(10), 3925-3934.
6. Singer, B. B.; Klaile, E.; Scheffrahn, I.; Muller, M. M.; Kammerer, R.; Reutter, W.; Obrink, B.; Lucka, L. CEACAM1 (CD66a) mediates delay of spontaneous and Fas ligand-induced apoptosis in granulocytes. Eur. J. Immunol., 2005, 35(6), 1949-1959.
7. van Gisbergen, K.P.; Ludwig, I.S.; Geijtenbeek, T.B.; van Kooyk, Y. Interactions of DC-SIGN with Mac-1 and CEACAM1 regulate contact between dendritic cells and neutrophils. FEBS. Lett., 2005, 579(27), 6159-6168.
8. Yoon, J.; Terada, A.; Kita, H. CD66b regulates adhesion and activation of human eosinophils. J. Immunol., 2007, 179(12), 8454-8462.
9. Yu, Q.; Chow, E. M.; Wong, H.; Gu, J.; Mandelboim, O.; Gray-Owen, S. D.; Ostrowski, M. A. CEACAM1 (CD66a) promotes human monocyte survival via a phosphatidylinositol 3-kinase-and AKT-dependent pathway. J. Biol. Chem., 2006, 281(51), 39179-93.
10. Greicius, G.; Severinson, E.; Beauchemin, N.; Obrink, B.; Singer, B.B. CEACAM1 is a potent regulator of B cell receptor complexinduced activation. J. Leukoc. Biol., 2003, 74(1), 126-134.
11. Nagaishi, T.; Iijima, H.; Nakajima, A.; Chen, D.; Blumberg, R.S. Role of CEACAM1 as a regulator of T cells. Ann. N Y. Acad. Sci., 2006, 1072, 155-175.
12. Horst, A. K.; Ito, W. D.; Dabelstein, J.; Schumacher, U.; Sander, H.; Turbide, C.; Brummer, J.; Meinertz, T.; Beauchemin, N.; Wagener, C. Carcinoembryonic antigen-related cell adhesion molecule 1 modulates vascular remodeling in vitro and in vivo. J. Clin. Invest., 2006, 116(6), 1596-1605.
13. Poliani, P. L.; Mitola, S.; Ravanini, M.; Ferrari-Toninelli, G.; D'Ippolito, C.; Notarangelo, L. D.; Bercich, L.; Wagener, C.; Memo, M.; Presta, M.; Facchetti, F. CEACAM1/VEGF cross-talk during neuroblastic tumour differentiation. J. Pathol., 2007, 211(5), 541-549.
14. Poy, M. N.; Yang, Y.; Rezaei, K.; Fernstrom, M. A.; Lee, A. D.; Kido, Y.; Erickson, S. K.; Najjar, S. M. CEACAM1 regulates insulin clearance in liver. Nat. Genet., 2002, 30(3), 270-276.
15. Najjar, S.M. Regulation of insulin action by CEACAM1. Trends Endocrinol. Metab., 2002, 13(6), 240-245.
16. Brummer, J.; Ebrahimnejad, A.; Flayeh, R.; Schumacher, U.; Loning, T.; Bamberger, A. M.; Wagener, C. cis Interaction of the cell adhesion molecule CEACAM1 with integrin beta(3). Am. J. Pathol., 2001, 159(2), 537-546.
17. Ebrahimnejad, A.; Streichert, T.; Nollau, P.; Horst, A. K.; Wagener, C.; Bamberger, A. M.; Brummer, J. CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. Am. J. Pathol., 2004, 165(5):1781-1787.
18. Busch, C.; Hanssen, T. A.; Wagener, C.; B, O. B. Down-regulation of CEACAM1 in human prostate cancer: correlation with loss of cell polarity, increased proliferation rate, and Gleason grade 3 to 4 transition. Hum. Pathol., 2002, 33(3):290-298.
19. Leung, N.; Turbide, C.; Balachandra, B.; Marcus, V.; Beauchemin, N. Intestinal tumor progression is promoted by decreased apoptosis and dysregulated Wnt signaling in Ceacam1-/-mice. Oncogene, 2008, 27(36), 4943-4953.
20. Leung, N.; Turbide, C.; Olson, M.; Marcus, V.; Jothy, S.; Beauchemin, N. Deletion of the carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1) gene contributes to colon tumor progression in a murine model of carcinogenesis. Oncogene, 2006, 25(40), 5527-5536.
21. Fedarovich, A.; Tomberg, J.; Nicholas, R. A.; Davies, C. Structure of the N-terminal domain of human CEACAM1: binding target of the opacity proteins during invasion of Neisseria meningitidis and N. gonorrhoeae. Acta Crystallogr. D. Biol. Crystallogr., 2006, 62(Pt 9), 971-979.
22. Leusch, H.G.; Drzeniek, Z.; Hefta, S.A.; Markos-Pusztai, Z.; Wagener, C. The putative role of members of the CEA-gene family (CEA, NCA an BGP) as ligands for the bacterial colonization of different human epithelial tissues. Zentralbl. Bakteriol., 1991, 275(1), 118-122.
23. Leusch, H.G.; Drzeniek, Z.; Markos-Pusztai, Z.; Wagener, C. Binding of Escherichia coli and Salmonella strains to members of the carcinoembryonic antigen family: differential binding inhibition by aromatic alpha-glycosides of mannose. Infect. Immun., 1991, 59(6), 2051-2057.
24. Sauter, S.L.; Rutherfurd, S.M.; Wagener, C.; Shively, J.E.; Hefta, S.A. Identification of the specific oligosaccharide sites recognized by type 1 fimbriae from Escherichia coli on nonspecific crossreacting antigen, a CD66 cluster granulocyte glycoprotein. J. Biol. Chem., 1993, 268(21), 15510-15516.
25. Conners, R.; Hill, D. J.; Borodina, E.; Agnew, C.; Daniell, S. J.; Burton, N. M.; Sessions, R. B.; Clarke, A. R.; Catto, L. E.; Lammie, D.; Wess, T.; Brady, R. L.; Virji, M. The Moraxella adhesin UspA1 binds to its human CEACAM1 receptor by a deformable trimeric coiled-coil. Embo. J., 2008, 27(12), 1779-1789.
26. Virji, M.; Evans, D.; Griffith, J.; Hill, D.; Serino, L.; Hadfield, A.; Watt, S. M. Carcinoembryonic antigens are targeted by diverse strains of typable and non-typable Haemophilus influenzae. Mol. Microbiol., 2000, 36(4), 784-795.
27. Markel, G.; Ortenberg, R.; Seidman, R.; Sapoznik, S.; Koren-Morag, N.; Besser, M. J.; Bar, J.; Shapira, R.; Kubi, A.; Nardini, G.; Tessone, A.; Treves, A. J.; Winkler, E.; Orenstein, A.; Schachter, J. Systemic dysregulation of CEACAM1 in melanoma patients. Cancer. Immunol. Immunother., 2009, 59(2), 215-230.
28. Draberova, L.; Cerna, H.; Brodska, H.; Boubelik, M.; Watt, S. M.; Stanners, C. P.; Draber, P. Soluble isoforms of CEACAM1 containing the A2 domain: increased serum levels in patients with obstructive jaundice and differences in 3-fucosyl-N-acetyllactosamine moiety. Immunology, 2000, 101(2), 279-287.
29. Kuroki, M.; Arakawa, F.; Matsuo, Y.; Oikawa, S.; Nakazato, H.; Matsuoka, Y. Three novel molecular forms of biliary glycoprotein deduced from cDNA clones from a human leukocyte library. Biochem. Biophys. Res. Commun., 1991, 176(2), 578.
30. Markel, G.; Lieberman, N.; Katz, G.; Arnon, T. I.; Lotem, M.; Drize, O.; Blumberg, R. S.; Bar-Haim, E.; Mader, R.; Eisenbach, L.; Mandelboim, O. CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J. Immunol., 2002, 168(6), 2803-2810.
31. Markel, G.; Gruda, R.; Achdout, H.; Katz, G.; Nechama, M.; Blumberg, R. S.; Kammerer, R.; Zimmermann, W.; Mandelboim, O. The critical role of residues 43R and 44Q of carcinoembryonic antigen cell adhesion molecules-1 in the protection from killing by human NK cells. J. Immunol., 2004, 173(6), 3732-3739.
32. Oikawa, S.; Kuroki, M.; Matsuoka, Y.; Kosaki, G.; Nakazato, H. Homotypic and heterotypic Ca(++)-independent cell adhesion activities of biliary glycoprotein, a member of carcinoembryonic antigen family, expressed on CHO cell surface. Biochem. Biophys. Res. Commun., 1992, 186(2), 881-887.
33. Singer, B.; Scheffrahn, I.; Obrink, B. The tumor growth-inhibiting cell adhesion molecule CEACAM1 (C-CAM) is differently expressed in proliferating and quiescent epithelial cells and regulates cell proliferation. Cancer Res., 2000, 60(5), 1236-1244.
34. Teixeira, A.M.; Fawcett, J.; Simmons, D.L.; Watt, S.M. The Ndomain of the biliary glycoprotein (BGP) adhesion molecule mediates homotypic binding: domain interactions and epitope analysis of BGPc. Blood, 1994, 84(1), 211-219.
35. Watt, S. M.; Teixeira, A. M.; Zhou, G. Q.; Doyonnas, R.; Zhang, Y.; Grunert, F.; Blumberg, R. S.; Kuroki, M.; Skubitz, K. M.; Bates, P. A. Homophilic adhesion of human CEACAM1 involves N-terminal domain interactions: structural analysis of the binding site. Blood, 2001, 98(5), 1469-1479.
36. Scheffrahn, I.; Singer, B.B.; Sigmundsson, K.; Lucka, L.; Obrink, B. Control of density-dependent, cell state-specific signal transduction by the cell adhesion molecule CEACAM1, and its influence on cell cycle regulation. Exp. Cell. Res., 2005, 307(2), 427-435.
37. Slevogt, H.; Zabel, S.; Opitz, B.; Hocke, A.; Eitel, J.; N'Guessan P, D.; Lucka, L.; Riesbeck, K.; Zimmermann, W.; Zweigner, J.; Temmesfeld-Wollbrueck, B.; Suttorp, N.; Singer, B. B. CEACAM1 inhibits Toll-like receptor 2-triggered antibacterial responses of human pulmonary epithelial cells. Nat. Immunol., 2008, 9(11), 1270-1278.
38. Markel, G.; Wolf, D.; Hanna, J.; Gazit, R.; Goldman-Wohl, D.; Lavy, Y.; Yagel, S.; Mandelboim, O. Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J. Clin. Invest., 2002, 110(7), 943-953.
39. Markel, G.; Mussaffi, H.; Ling, K.-L.; Salio, M.; Gadola, S.; Steuer, G.; Blau, H.; Achdout, H.; de Miguel, M.; Gonen-Gross, T.; Hanna, J.; Arnon, T. I.; Qimron, U.; Volovitz, I.; Eisenbach, L.; Blumberg, R. S.; Porgador, A.; Cerundolo, V.; Mandelboim, O. The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood, 2004, 103(5), 1770-1778.
40. Lobo, E. O.; Zhang, Z.; Shively, J. E. Pivotal advance: CEACAM1 is a negative coreceptor for the B cell receptor and promotes CD19-mediated adhesion of B cells in a PI3K-dependent manner. J. Leukoc. Biol., 2009, 86(2), 205-218.
41. Chen, C.J.; Shively, J.E. The cell-cell adhesion molecule carcinoembryonic antigen-related cellular adhesion molecule 1 inhibits IL-2 production and proliferation in human T cells by association with Src homology protein-1 and down-regulates IL-2 receptor. J. Immunol., 2004, 172(6), 3544-3552.
42. Nagaishi, T.; Pao, L.; Lin, S. H.; Iijima, H.; Kaser, A.; Qiao, S. W.; Chen, Z.; Glickman, J.; Najjar, S. M.; Nakajima, A.; Neel, B. G.; Blumberg, R. S. SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity, 2006, 25(5), 769-781.
43. Boulton, I.C.; Gray-Owen, S.D. Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes. Nat. Immunol., 2002, 3(3), 229-236.
44. Skubitz, K.M.; Campbell, K.D.; Skubitz, A.P. CD66a, CD66b, CD66c, and CD66d each independently stimulate neutrophils. J. Leukoc. Biol., 1996, 60(1), 106-117.
45. Chen, Z.; Chen, L.; Qiao, S.W.; Nagaishi, T.; Blumberg, R.S. Carcinoembryonic antigen-related cell adhesion molecule 1 inhibits proximal TCR signaling by targeting ZAP-70. J. Immunol., 2008, 180(9), 6085-6093.
46. Lee, H.S.W.; Ostrowski, M.A.; Gray-Owen, S.D. CEACAM1 Dynamics during Neisseria gonorrhoeae Suppression of CD4+ T Lymphocyte Activation. J. Immunol., 2008, 180(10), 6827-6835.
47. Chen, T.; Zimmermann, W.; Parker, J.; Chen, I.; Maeda, A.; Bolland, S. Biliary glycoprotein (BGPa, CD66a, CEACAM1) mediates inhibitory signals. J. Leukoc. Biol., 2001, 70(2), 335-340.
48. Huber, M.; Izzi, L.; Grondin, P.; Houde, C.; Kunath, T.; Veillette, A.; Beauchemin, N. The Carboxyl-terminal Region of Biliary Glycoprotein Controls Its Tyrosine Phosphorylation and Association with Protein-tyrosine Phosphatases SHP-1 and SHP-2 in Epithelial Cells. J. Biol. Chem., 1999, 274(1), 335-344.
49. Muller, M.M.; Klaile, E.; Vorontsova, O.; Singer, B.B.; Obrink, B. Homophilic adhesion and CEACAM1-S regulate dimerization of CEACAM1-L and recruitment of SHP-2 and c-Src. J. Cell. Biol., 2009, 187(4), 569-581.
50. Schumann, D.; Chen, C.J.; Kaplan, B.; Shively, J.E. Carcinoembryonic antigen cell adhesion molecule 1 directly associates with cytoskeleton proteins actin and tropomyosin. J. Biol. Chem., 2001, 276(50), 47421-47433.
51. Edlund, M.; Blikstad, I.; Obrink, B. Calmodulin binds to specific sequences in the cytoplasmic domain of C-CAM and downregulates C-CAM self-association. J. Biol. Chem., 1996, 271(3),1393-1399.
52. Jin, L.; Li, Y.; Chen, C.J.; Sherman, M.A.; Le, K.; Shively, J.E. Direct Interaction of Tumor Suppressor CEACAM1 with Beta Catenin: Identification of Key Residues in the Long Cytoplasmic Domain. Exp. Biol. Med. (Maywood)., 2008, 233(7), 849-859.
53. Turbide, C.; Kunath, T.; Daniels, E.; Beauchemin, N. Optimal ratios of biliary glycoprotein isoforms required for inhibition of colonic tumor cell growth. Cancer Res., 1997, 57(13), 2781-2788.
54. Gaur, S.; Shively, J.E.; Yen, Y.; Gaur, R.K. Altered splicing of CEACAM1 in breast cancer: identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms. Mol. Cancer, 2008, 7, 46.
55. Rosenberg, M.; Nedellec, P.; Jothy, S.; Fleiszer, D.; Turbide, C.; Beauchemin, N. The expression of mouse biliary glycoprotein, a carcinoembryonic antigen-related gene, is down-regulated in malignant mouse tissues. Cancer Res., 1993, 53(20), 4938-4945.
56. Neumaier, M.; Paululat, S.; Chan, A.; Matthaes, P.; Wagener, C. Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas. Proc. Natl. Acad. Sci. USA, 1993, 90(22), 10744-10748.
57. Tanaka, K.; Hinoda, Y.; Takahashi, H.; Sakamoto, H.; Nakajima, Y.; Imai, K. Decreased expression of biliary glycoprotein in hepatocellular carcinomas. Int. J. Cancer., 1997, 74(1), 15-19.
58. Tilki, D.; Irmak, S.; Oliveira-Ferrer, L.; Hauschild, J.; Miethe, K.; Atakaya, H.; Hammerer, P.; Friedrich, M. G.; Schuch, G.; Galalae, R.; Stief, C. G.; Kilic, E.; Huland, H.; Ergun, S. CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer. Oncogene, 2006, 25(36), 4965-4974.
59. Oliveira-Ferrer, L.; Tilki, D.; Ziegeler, G.; Hauschild, J.; Loges, S.; Irmak, S.; Kilic, E.; Huland, H.; Friedrich, M.; Ergun, S. Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer. Cancer Res., 2004, 64(24), 8932-8938.
60. Kammerer, R.; Riesenberg, R.; Weiler, C.; Lohrmann, J.; Schleypen, J.; Zimmermann, W. The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma. J. Pathol., 2004, 204(3), 258-267.
61. Kunath, T.; Ordonez-Garcia, C.; Turbide, C., Beauchemin, N. Inhibition of colonic tumor cell growth by biliary glycoprotein. Oncogene, 1995, 11(11), 2375-2382.
62. Hsieh, J. T.; Luo, W.; Song, W.; Wang, Y.; Kleinerman, D. I.; Van, N. T.; Lin, S. H. Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res., 1995, 55(1), 190-197.
63. Markel, G.; Seidman, R.; Stern, N.; Cohen-Sinai, T.; Izhaki, O.; Katz, G.; Besser, M.; Treves, A. J.; Blumberg, R. S.; Loewenthal, R.; Mandelboim, O.; Orenstein, A.; Schachter, J. Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. J. Immunol., 2006, 177(9), 6062-6071.
64. Markel, G.; Seidman, R.; Cohen, Y.; Besser, M. J.; Sinai, T. C.; Treves, A. J.; Orenstein, A.; Berger, R.; Schachter, J. Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology, 2009, 126(2), 186-200.
65. Liu, W.; Wei, W.; Winer, D.; Bamberger, A. M.; Bamberger, C.; Wagener, C.; Ezzat, S.; Asa, S. L. CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene, 2007, 26(19), 2747-2758.
66. Dango, S.; Sienel, W.; Schreiber, M.; Stremmel, C.; Kirschbaum, A.; Pantel, K.; Passlick, B. Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) is associated with increased angiogenic potential in non-small-cell lung cancer. Lung Cancer, 2008, 60(3), 426-433.
67. Kinugasa, T.; Kuroki, M.; Takeo, H.; Matsuo, Y.; Ohshima, K.; Yamashita, Y.; Shirakusa, T.; Matsuoka, Y. Expression of four CEA family antigens (CEA, NCA, BGP and CGM2) in normal and cancerous gastric epithelial cells: up-regulation of BGP and CGM2 in carcinomas. Int. J. Cancer, 1998, 76(1), 148-153.
68. Thies, A.; Moll, I.; Berger, J.; Wagener, C.; Brummer, J.; Schulze, H. J.; Brunner, G.; Schumacher, U. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J. Clin. Oncol., 2002, 20(10), 2530-2536.
69. Laack, E.; Nikbakht, H.; Peters, A.; Kugler, C.; Jasiewicz, Y.; Edler, L.; Brummer, J.; Schumacher, U.; Hossfeld, D. K. Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J. Clin. Oncol., 2002, 20(21), 4279-4284.
70. Obrink, B. On the role of CEACAM1 in cancer. Lung Cancer, 2008, 60(3), 309-312.
71. Lens, M.; Dawes, M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br. J. Dermatol., 2004, 150, 179-185.
72. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Thun, M.J. Cancer Statistics, 2007. CA. Cancer J. Clin., 2007, 57(1), 43-66.
73. Sladden, M.J.; Balch, C.; Barzilai, D.A.; Berg, D.; Freiman, A.; Handiside, T.; Hollis, S.; Lens, M.B.; Thompson, J.F. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst. Rev., 2009, 4, CD004835.
74. Lens, M. The role of vaccine therapy in the treatment of melanoma. Expert. Opin. Biol. Ther., 2008, 8(3), 315-323.
75. Tawbi, H. A; Kirkwood, J.M. Management of metastatic melanoma. Semin. Oncol., 2007, 34(6), 532-545.
76. Lens, M.; Ferrucci, P.F.; Testori, A. Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings. Recent Pat. Anticancer Drug Discov., 2008, 3(2), 105-113.
77. Rosenberg, S.A.; Restifo, N.P.; Yang, J.C.; Morgan, R.A.; Dudley, M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer, 2008, 8(4), 299-308.
78. Kadison, A.S.; Morton, D.L. Immunotherapy of malignant melanoma. Surg. Clin. North Am., 2003, 83(2), 343-370.
79. Rosenberg, S.A.; Yang, J.C.; White, D.E.; Steinberg, S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg., 1998, 228(3), 307-319.
80. Spanknebel, K.; Cheung, K. Y.; Stoutenburg, J.; Hurst-Wicker, K.; Hesdorffer, C.; Rn, G. D.; Kaufman, A. H. Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2. Ann. Surg. Oncol., 2005, 12(5), 381-90.
81. Rosenberg, S.A.; Yang, J.C.; Restifo, N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med., 2004, 10(9), 909-915.
82. Rosenberg, S.A.; Sherry, R.M.; Morton, K.E.; Scharfman, W.J.; Yang, J.C.; Topalian, S.L.; Royal, R.E.; Kammula, U.; Restifo, N.P.; Hughes, M.S.; Schwartzentruber, D.; Berman, D.M.; Schwarz, S.L.; Ngo, L.T.; Mavroukakis, S.A.; White, D.E.; Steinberg, S.M. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol., 2005, 175(9), 6169-6176.
83. Dudley, M. E.; Wunderlich, J. R.; Yang, J. C.; Sherry, R. M.; Topalian, S. L.; Restifo, N. P.; Royal, R. E.; Kammula, U.; White, D. E.; Mavroukakis, S. A.; Rogers, L. J.; Gracia, G. J.; Jones, S. A.; Mangiameli, D. P.; Pelletier, M. M.; Gea-Banacloche, J.; Robinson, M. R.; Berman, D. M.; Filie, A. C.; Abati, A.; Rosenberg, S. A. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol., 2005, 23(10), 2346-2357.
84. Dudley, M. E.; Wunderlich, J. R.; Robbins, P. F.; Yang, J. C.; Hwu, P.; Schwartzentruber, D. J.; Topalian, S. L.; Sherry, R.; Restifo, N. P.; Hubicki, A. M.; Robinson, M. R.; Raffeld, M.; Duray, P.; Seipp, C. A.; Rogers-Freezer, L.; Morton, K. E.; Mavroukakis, S. A.; White, D. E.; Rosenberg, S. A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 2002, 298(5594):850-854.
85. Besser, M. J.; Shapira-Frommer, R.; Treves, A. J.; Zippel, D.; Itzhaki, O.; Schallmach, E.; Kubi, A.; Shalmon, B.; Hardan, I.; Catane, R.; Segal, E.; Markel, G.; Apter, S.; Nun, A. B.; Kuchuk, I.; Shimoni, A.; Nagler, A.; Schachter, J. Minimally cultured or se lected autologous tumor-infiltrating lymphocytes after a lymphodepleting chemotherapy regimen in metastatic melanoma patients. J. Immunother., 2009, 32(4), 415-423.
86. Gambichler, T.; Grothe, S.; Rotterdam, S.; Altmeyer, P.; Kreuter, A. Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions. Am. J. Clin. Pathol., 2009, 131(6), 782-787.
87. Thies, A.; Mauer, S., Fodstad, O.; Schumacher, U. Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice. Br. J. Cancer, 2007, 96(4), 609-616.
88. Christianson, D.F.; Anderson, C.M. Close monitoring and lifetime follow-up is optimal for patients with a history of melanoma. Sem. Oncol., 2003, 30(3), 369.
89. Barnhill, R.L.; Piepkorn, M.W.; Cochran, A.J.; Flynn, E.; Karaoli, T.; Folkman, J. Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases. Arch. Dermatol., 1998, 134(8), 991-994.
90. Gogas, H.; Eggermont, A. M.; Hauschild, A.; Hersey, P.; Mohr, P.; Schadendorf, D.; Spatz, A.; Dummer, R. Biomarkers in melanoma. Ann. Oncol., 2009, 20(Suppl 6), vi8-13.
91. Harpio, R.; Einarsson, R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin. Biochem., 2004, 37(7), 512-518.
92. Bien, E.; Balcerska, A. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with hodgkin's lymphoma. Scand. J. Immunol., 2009, 70(5), 490-500.
93. Laham, F. R.; Trott, A. A.; Bennett, B. L.; Kozinetz, C. A.; Jewell, A. M.; Garofalo, R. P.; Piedra, P. A. LDH concentration in nasalwash fluid as a biochemical predictor of bronchiolitis severity. Pediatrics 2010, 125(2), e225-233.
94. Tetsuya, F.; Satoru, T.; Tomohiko, U.; Liu, X.; Tetsuo, O.; Masami, M.; Yasuyoshi, O.; Tadaichi, K.; Yukio, H.; Satoshi, I. Estrogen receptor-binding fragment-associated gene 9 expression and its clinical significance in human testicular cancer. Int. J. Urol., 2009, 16(3), 329-332.
95. Terahara, K.; Yoshida, M.; Taguchi, F.; Igarashi, O.; Nochi, T.; Gotoh, Y.; Yamamoto, T.; Tsunetsugu-Yokota, Y.; Beauchemin, N.; Kiyono, H. Expression of newly identified secretory CEACAM1(a) isoforms in the intestinal epithelium. Biochem. Biophys. Res. Commun., 2009, 383(3), 340-346.
96. Chan, A.D.; Essner, R.; Wanek, L.A.; Morton, D.L. Judging the therapeutic value of lymph node dissections for melanoma. J. Am. Coll. Surg., 2000, 191(1),16.
97. Kleineidam, M.; Guthoff, R.; Bentzen, S. Rates of local control, metastasis, and overall survival in patients with posterior uveal melanomas treated with ruthenium-106 plaques. Radiother. Oncol., 1993, 28(2), 148-156.
98. Schnickmann, S.; Camacho-Trullio, D.; Bissinger, M.; Eils, R.; Angel, P.; Schirmacher, P.; Szabowski, A.; Breuhahn, K. AP-1-Controlled hepatocyte rowth factor activation promotes keratinocyte migration via CEACAM1 and urokinase Plasminogen Activator/ Urokinase Plasminogen Receptor. J. Invest. Dermatol., 2009, 129(5), 1140-1148.
99. Klaile, E.; Muller, M.M.; Kannicht, C.; Singer, B.B.; Lucka, L. CEACAM1 functionally interacts with filamin A and exerts a dual role in the regulation of cell migration. J. Cell. Sci., 2005, 118(Pt 23), 5513-5524.
100. Azuz-Lieberman, N.; Markel, G.; Mizrahi, S. a.; Gazit, R.; Hanna, J.; Achdout, H.; Gruda, R.; Katz, G.; Arnon, T. I.; Battat, S.; Zamir, E.; Adawi, M.; Mader, R.; Mandelboim, O. The involvement of NK cells in ankylosing spondylitis. Int. Immunol., 2005, 17(7), 837-845.
101. Markel, G.; Achdout, H.; Katz, G.; Ling, K. L.; Salio, M.; Gruda, R.; Gazit, R.; Mizrahi, S.; Hanna, J.; Gonen-Gross, T.; Arnon, T. I.; Lieberman, N.; Stren, N.; Nachmias, B.; Blumberg, R. S.; Steuer, G.; Blau, H.; Cerundolo, V.; Mussaffi, H.; Mandelboim, O. Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients. Eur. J. Immunol., 2004, 34(8), 2138-2148.
102. Kammerer, R.; Stober, D.; Singer, B.B.; Obrink, B.; Reimann, J. Carcinoembryonic antigen-related cell adhesion molecule 1 on murine dendritic cells is a potent regulator of T cell stimulation. J. Immunol., 2001, 166(11), 6537-6544.
103. Nagaishi, T.; Chen, Z.; Chen, L.; Iijima, H.; Nakajima, A.; Blumberg, RS. CEACAM1 and the regulation of mucosal inflammation. Mucosal Immunol., 2008, 1(suppl 1), S39-42.
104. Ljunggren, H.; Kärre, K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today, 1990, 11(7), 237-244.
105. Bulmer, J.N.; Morrison, L.; Longfellow, M.; Ritson, A.; Pace, D. Granulated lymphocytes in human endometrium: histochemical and immunohistochemical studies. Hum. Reprod., 1991, 6(6), 791-798.
106. Restifo, N.P.; Marincola, F.M.; Kawakami, Y.; Taubenberger, J.; Yannelli, J.R.; Rosenberg, S.A. Loss of functional beta2-microglobulin in metastatic melanomas From Five Patients Receiving Immunotherapy. J. Natl. Cancer Inst., 1996, 88(2), 100-108.
107. Stern, N.; Markel, G.; Arnon, T. I.; Gruda, R.; Wong, H.; Gray-Owen, S. D. Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J. Immunol., 2005, 174(11),6692-6701.